In ER/PR + HER2- and HER2+ breast cancers, C1 tended to be associated with a worse prognosis compared to C2, and C1 exhibited lower immune scores than C2 (Figure S2D–F). This evidence concerns the gene ERBB2 and breast carcinoma.